Gonorrhea: Treatment and management considerations for the male patient

Brian Dalke; Timothy Ivers; Karen K. O’Brien; Shana Castillo; Eric Hoie; Kimberley J. Begley

Gonorrhea: Treatment and management considerations for the male patient

Brian Dalke, Timothy Ivers, Karen K. O’Brien, Shana Castillo, Eric Hoie, Kimberley J. Begley

Department of Pharmacy Practice

Research output: Contribution to specialist publication › Article

1 Scopus citations

Abstract

Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.

Original language	English (US)
Pages	41-44
Number of pages	4
Volume	41
No	8
Specialist publication	U.S. Pharmacist
State	Published - Aug 1 2016

All Science Journal Classification (ASJC) codes

Pharmacy
Pharmacology
Pharmaceutical Science

Access to Document

Fingerprint Dive into the research topics of 'Gonorrhea: Treatment and management considerations for the male patient'. Together they form a unique fingerprint.

Cite this

@misc{67fabf5d7f3b44b08b3682c139423db3,

title = "Gonorrhea: Treatment and management considerations for the male patient",

abstract = "Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.",

author = "Brian Dalke and Timothy Ivers and O{\textquoteright}Brien, {Karen K.} and Shana Castillo and Eric Hoie and Begley, {Kimberley J.}",

year = "2016",

month = aug,

day = "1",

language = "English (US)",

volume = "41",

pages = "41--44",

journal = "U.S. Pharmacist",

issn = "0148-4818",

publisher = "Jobson Publishing Corporation",

}

TY - GEN

T1 - Gonorrhea

T2 - Treatment and management considerations for the male patient

AU - Dalke, Brian

AU - Ivers, Timothy

AU - O’Brien, Karen K.

AU - Castillo, Shana

AU - Hoie, Eric

AU - Begley, Kimberley J.

PY - 2016/8/1

Y1 - 2016/8/1

N2 - Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.

AB - Gonorrhea is the second most common communicable disease in the United States. From 2010 to 2014, the rate of this sexually transmitted disease increased by 10.5% in the U.S. Cefixime, which was once the first-line agent for the treatment of Neisseria gonorrhoeae, is rapidly waning in efficacy, as are several other cephalosporins. Similarly, fluoroquinolone-resistant strains of N gonorrhoeae have been reported. As a result, the use of these agents has decreased. The CDC currently recommends dual treatment with ceftriaxone and azithromycin for most gonococcal infections. Multidrug-resistant gonorrhea is becoming a serious health threat in the U.S.

UR - http://www.scopus.com/inward/record.url?scp=84983070756&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84983070756&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:84983070756

VL - 41

SP - 41

EP - 44

JO - U.S. Pharmacist

JF - U.S. Pharmacist

SN - 0148-4818

ER -